Frederick Beddingfield III, MD, PhD is Founder, President and CEO of Sienna Biopharmaceuticals, Inc., a company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics.
Dr. Beddingfield is also a board-certified dermatologist and dermatologic surgeon and served as Chief Medical Officer of Kythera Biopharmaceuticals from 2013 until it was acquired by Allergan in 2015. He was employed at Allergan for ten years during the establishment and meteoric growth of the medical aesthetic market where he served as the Chief Medical Officer for Allergan Medical and Therapeutic Area Head, Dermatology and Aesthetics. Dr. Beddingfield led the development of premier global, market-leading brands in the dermatology and aesthetics industry, including BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, KYBELLA®, LATISSE®, ACZONE®, and RHOFADE®.
Dr. Beddingfield earned an MD Degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies.
Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Aclaris Therapeutics (NASDAQ: ACRS), Ascendis Pharma A/S (NASDAQ: ASND), ProNAi Therapeutics (NASDAQ: DNAI), Carbylan Therapeutics (NASDAQ: CBYL), AirXpanders (ASX: AXP), and several private companies. He was an investor in Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG).
Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer. Albert received his B.S. and M.S. in Electrical Engineering from Stanford University. He subsequently completed the Medical Scientist Training Program at UCLA School of Medicine, where he received his M.D. and Ph.D. in Neuroscience.
John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $1B in assets under management.
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of Zoomi, Inc., is currently a member of the board of directors for Zoomi, Inc. and for Brickell Biotech, Inc., has been a trustee of the Morristown Medical Center Foundation, and serves on the Advisory Council for the Keller Center of entrepreneurship at Princeton University.
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Dr. Neal Walker co-founded Aclaris Therapeutics and has served as President and Chief Executive Officer and a member of the board of directors since inception July 2012. He is a board certified dermatologist and serial entrepreneur with over 19 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson, Inc.
Dr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in August 2012. Prior to Aclaris, he co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the Board of Directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies.
In 2016 Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award, and also the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology, received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine, and a B.A. degree in Biology from Lehigh University.
Angela joined Dermira in 2015 and serves as Vice President of Patient Value. Angela has nearly 20 years of biotech and pharmaceutical experience with the majority of time focused in the dermatology therapeutic and consumer market. Prior to Dermira, Angela served as Vice President, Medical Relations at SkinCeuticals, a L'Oréal company. She has held various leadership roles in medical relations, sales, marketing and business development at organizations including L'Oréal, Stiefel, Connetics, Indevus, Inc., Johnson & Johnson and Alza. She is a member of numerous associations including the American Academy of Dermatology, Women's Dermatologic Society, American Society for Laser Medicine & Surgery, National Psoriasis Foundation, Acne & Rosacea Society and the Healthcare Businesswomen's Association. She has served on the Industry Advisory Council for the American Society for Dermatologic Surgery.
Angela earned a B.S. in marketing and business administration from Limestone College.
Alex Martin joined Realm Therapeutics in June 2015 as Chief Executive Officer and Executive Director. He brings nearly 30 years of experience as a senior executive in private and public biopharmaceutical companies. He previously served as Chief Executive Officer of Affectis Pharmaceuticals AG, Chief Operating Officer of Intercept Pharmaceuticals (NASD: ICPT), and Chief Financial Officer at BioXell S.p.A., which was acquired by Cosmo Pharmaceuticals S.A. Mr. Martin began his career at SmithKline Beecham Pharmaceuticals before joining Novartis as Vice President, Global Business Development & Licensing. Most recently, he served as President of moksha8, a leading Latin American specialty pharmaceutical company. In his various roles, he has built teams, raised multiple rounds of capital and closed transformative deals with world-class companies. Mr. Martin holds a BA from Cornell University and an MBA from The Harvard Business School.
Mr. Partridge brings marketing and communications experience spanning more than 20 years in the pharmaceutical industry to the CLS team. It marks the third major pharmaceutical effort headed up by Robert J. Bitterman, Sr., of which he's been a part. He earned separate degrees in Business Administration/Marketing and International Politics, and has an extensive track record of successful messaging and positioning of brands and promotional campaigns both in and outside of U.S. markets. He has been a key member of launch and pre-launch teams for Sanofi-Aventis companies in the fields of oncology, hematology, and neurology prior to moving into dermatology in 1996. He led the launch of the first monoclonal antibody purified factor VIII replacement product, and worked on the pre-launch of Rhone-Poulenc Rorer's lead chemotherapy product in the U.S., Taxotere. He also was part of the launch team for the first and only product approved by the FDA to treat amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease. His work also included a joint project with Dr. Jonas Salk's 'Immune Response Corporation' which at the time was attempting to develop a successful vaccine for HIV.
Within the dermatology specialty Mr. Partridge has experience with both medical and cosmetic product launches from a marketing and public relations perspective. He is the past Chairman for the Board of Directors of the Greater West Chester (PA) Chamber of Commerce. He also sits on two other non-profit Boards in the Southeastern Pennsylvania region, for the Franklin Mint Federal Credit Union with assets over $1 billion, and the West Chester Area Education Foundation.
Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline’s Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 24 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.
N. Nicole Stakleff is a partner with Pepper Hamilton LLP, resident in the Pittsburgh office. A registered patent attorney since 2002, Ms. Stakleff concentrates her practice in intellectual property law, including strategic patent prosecution and counseling and due diligence in the pharmaceutical, chemical, medical and other life sciences fields.
Dr. Shiv Taylor is a Senior Managing Director in the Healthcare Investment Banking group at Guggenheim. He focuses on Biotechnology and Pharmaceutical companies. Prior to joining Guggenheim, he was at Deutsche Bank in the Healthcare Investment Banking group. Prior to investment banking, Dr. Taylor was Head of Healthcare Investments at Plainfield Asset Management and a General Surgery Fellow at Harvard Medical School, Beth Israel Deaconess Medical Center.
Jean-Jacques is President & CEO of Pierre Fabre Dermatologie (PFD), a global brand dedicated to Medical Dermatology operating in 80 countries. PFD is a brand from Pierre Fabre Group, a 2,3 B€ french pharma company, known for its expertise in dermatology, dermo-cosmetics and oncology.
Since he joined PFD in Nov.2003, and before being appointed President & CEO of PFD in 2013, Jean-Jacques has held several positions in PFD (Head of Medical Affairs, Head of Marketing/Development, Head of the French Subsidiary where PFD lead the market in terms of drug prescriptions by dermatologists). PFD is amongst the Top 10 global companies in Medical Dermatology in the world.
Jean-Jacques has led the worldwide development of Hemangiol, the first and only oral solution of propranolol specifically designed for safe and effective use in infants with Infantile Hemangiomas requiring systemic therapy (orphan condition). The development included an innovative phase II/III clinical trial, with results published in New England Journal of Medicine in 2015. Hemangiol is currently approved in 34 countries (EU, USA, Switzerland, Australia), with many other approvals expected in the coming years. Hemangiol was awarded "Drug of the year in 2014 in France" by the Prix Galien. Currently, PFD focus its R&D efforts in Orphan skin diseases, Pediatric Dermatology and Dermato-Oncology.
Prior to joining Pierre Fabre, Jean-Jacques was General Manager for Aster Dermatologie, a french CRO fully dedicated to the clinical evaluation of dermo-cosmetic products and drugs in dermatology, where he had the opportunity to conduct clinical trials for major companies in dermatology. Jean-Jacques is a board certified dermatologist and was trained in Bordeaux (France).
Warren J. Winkelman, MD, PhD, MBA, FAAD, FRCPC is Senior Medical Director and Head of Medical Innovation for the Nestlé Skin Health Investigation, Education and Longevity Development (SHIELD) Center in New York. SHIELD, launched in December 2014, is a global network of innovative cross-discipline experts and visionaries working every day to develop new approaches in skin health, nutrition and wellness in this era of unprecedented longevity.
Warren holds a PhD in ehealth innovation, health policy, management and evaluation from the University of Toronto and an MBA in healthcare administration from SUNY-Binghamton School of Management. He was awarded a Canadian Institutes of Health Research (CIHR) fellowship in ehealth innovation science, and has conducted research under the auspices of the Center for Global eHealth Innovation (Toronto), the Canadian Dermatology Foundation (CDF) and the National Research Council-Canada (NRC) to help promote the empowerment of patients living with chronic skin disease and their caregivers through information and communication technologies.
Warren is a board-certified dermatologist with more than 25 years' experience in patient care, medical education, research, and has held medical leadership roles at Schering-Plough, Merck, Janssen and Galderma. He is a graduate of the Sophie Davis School of Biomedical Education at City College of New York, receiving his MD from the State University of New York (SUNY) at Buffalo School of Medicine and Biomedical Sciences, and completing his dermatology residency at McGill University.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.